Owlstone Ltd
About
Company description
Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by breath-based diagnostics, through the development and application of Breath Biopsy®. Breath Biopsy operates by detecting volatile organic compounds (VOCs) produced as the end product of metabolic processes within the body or as a result of chemicals from external sources such as diet or medication, changes in which can be characteristic of specific disease or indicate environmental exposure.
Quick facts
Sales markets | Africa; Asia; Australia; Central/South America; Eastern Europe; Middle East; North America; Western Europe |
---|---|
Primary business activity | Contract Manufacturer |
Affiliated categories: | Analysis |Contract Research |Lab service & equipment More |
Recently at
Vitafoods Europe 2024
14 - 16 May 2024 - Geneva, Switzerland We were at stand P254 See our Exhibitor Profile See full Exhibitor ListNews about Owlstone Ltd
23 Jun 2023
OMED Health Featured on BBC Click
We are delighted to see our CEO Billy Boyle featured on BBC Click’s program discussing how breath analysis can revolutionize monitoring technology to empower patients and their doctors to improve healthcare decision-making.
Read more23 Jun 2023
Owlstone Medical Launches OMED Health
Owlstone Medical launches OMED Health to enable patients to better understand their gut microbiome and manage their digestive health.
Read more